Temporal gene expression profiling indicates early up-regulation of interleukin-6 in isoproterenol-induced myocardial necrosis in rat

Toxicologic Pathology

Volumn 36, Issue 2, 2008, Pages 256-264

  Mikaelian, Igor ^a   Coluccio, Denise ^a   Morgan, Kevin T ^b   Johnson, Teona ^a   Ryan, Amber L ^a   Rasmussen, Erik ^a   Nicklaus, Rosemary ^a   Kanwal, Charu ^a   Hilton, Holly ^a   Frank, Karl ^a   Fritzky, Luke ^a   Wheeldon, Eric B ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b SANOFI   (France)

Author keywords

Affymetrix; Gene expression; Interleukin 6; Isoproterenol; Myocardium; Rat; Transcriptomic

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FATTY ACID; HEMATOXYLIN; I KAPPA B KINASE GAMMA; INTERLEUKIN 6; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOTUNGSTIC ACID; TROPONIN I;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CLINICAL CHEMISTRY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FATTY ACID METABOLISM; GENE EXPRESSION; HEART CONTRACTION; HEART MUSCLE NECROSIS; HEMATOLOGY; HISTOLOGY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STAINING; UPREGULATION;

ADRENERGIC BETA-AGONISTS; ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HEART; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-6; ISOPROTERENOL; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, WISTAR; RNA, MESSENGER; TIME FACTORS; TROPONIN I; UP-REGULATION;

RATTUS; RATTUS NORVEGICUS;

EID: 42149140618     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623307312696     Document Type: Article

References (51)

1. Aasum, E., Hafstad, A.D., and Larsen, T.S. (2003). Changes in substrate metabolism in isolated mouse hearts following ischemia-reperfusion. Mol Cell Biochem 249, 97-103.
2. Asakawa, M., Takano, H., Nagai, T., Uozumi, H., Hasegawa, H., Kubota, N., Saito, T., Masuda, Y., Kadowaki, T., and Komuro, I. (2002). Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105, 1240-6.
3. Barger, P.M., and Kelly, D.P. (1999). Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci 318, 36-42.
4. Bloom, S., and Cancilla, P.A. (1969). Myocytolysis and mitochondrial calcification in rat myocardium after low doses of isoproterenol. Am J Pathol 54, 373-91.
5. Boluyt, M.O., Long, X., Eschenhagen, T., Mende, U., Schmitz, W., Crow, M.T., and Lakatta, E.G. (1995). Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am J Physiol 269, H638-47.
6. Brand, T., Sharma, H.S., and Schaper, W. (1993). Expression of nuclear proto-oncogenes in isoproterenol-induced cardiac hypertrophy. J Mol Cell Cardiol 25, 1325-37.
7. Burger, A., Benicke, M., Deten, A., and Zimmer, H.G. (2001). Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 281, H14-21.
8. Chandrasekar, B., Mitchell, D.H., Colston, J.T., and Freeman, G.L. (1999). Regulation of CCAAT/Enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion. Circulation 99, 427-33.
9. Craig, R., Larkin, A., Mingo, A.M., Thuerauf, D.J., Andrews, C., McDonough, P.M., and Glembotski, C.C. (2000). p38 MAPK and NFkappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 275, 23814-24.
10. Cuzzocrea, S., De Sarro, G., Costantino, G., Ciliberto, G., Mazzon, E., De Sarro, A., and Caputi, A.P. (1999). IL-6 knock-out mice exhibit resistance to splanchnic artery occlusion shock. J Leukoc Biol 66, 471-80.
11. Dhalla, N.S., Yates, J.C., Naimark, B., Dhalla, K.S., Beamish, R.E., and Ostadal, B. (1992). Cardiotoxicity of catecholamines and related agents. In Cardiovascular Toxicology (D. Acosta, ed., pp. 239-82). Raven Press, New York.
12. Dunnick, J., Blackshear, P., Kissling, G., Cunningham, M., Parker, J., and Nyska, A. (2006). Critical pathways in heart function: bis(2-chloroethoxy) methane-induced heart gene transcript change in F344 rats. Toxicol Pathol 34, 348-56.
13. Edgley, A.J., Thalen, P.G., Dahllof, B., Lanne, B., Ljung, B., and Oakes, N.D. (2006). PPARgamma agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats. Eur J Pharmacol 538, 195-206.
14. Eriksson, U., Kurrer, M.O., Schmitz, N., Marsch, S.C., Fontana, A., Eugster, H.P., and Kopf, M. (2003). Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 107, 320-5.
15. Freed, D.H., Borowiec, A.M., Angelovska, T., and Dixon, I.M. (2003). Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways. Cardiovasc Res 60, 365-75.
16. Gaussin, V., Tomlinson, J.E., Depre, C., Engelhardt, S., Antos, C.L., Takagi, G., Hein, L., Topper, J.N., Liggett, S.B., Olson, E.N., Lohse, M.J., Vatner, S.F., and Vatner, D.E. (2003). Common genomic response in different mouse models of beta-adrenergic-induced cardiomyopathy. Circulation 108, 2926-33.
17. Goebel, M.U., Mills, P.J., Irwin, M.R., and Ziegler, M.G. (2000). Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: differential effects and pathways. Psychosom Med 62, 591-8.
18. Heinrich, P.C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt 2). 297-314.
19. Ikeda, U., Ohkawa, F., Seino, Y., Yamamoto, K., Hidaka, Y., Kasahara, T., Kawai, T., and Shimada, K. (1992). Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 24, 579-84.
20. Irizarry, R.A., Bolstad, B.M., Collin, F., Cope, L.M., Hobbs, B., and Speed, T.P. (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31, e15.
21. Ishizawa, M., Mizushige, K., Noma, T., Namba, T., Guo, P., Murakami, K., Tsuji, T., Miyatake, A., Ohmori, K., and Kohno, M. (2006). An antioxidant treatment potentially protects myocardial energy metabolism by regulating uncoupling protein 2 expression in a chronic beta-adrenergic stimulation rat model. Life Sci 78, 2974-82.
22. Izumo, S., Nadal-Ginard, B., and Mahdavi, V. (1988). Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A 85, 339-43.
23. Jacoby, J.J., Kalinowski, A., Liu, M.G., Zhang, S.S., Gao, Q., Chai, G.X., Ji, L., Iwamoto, Y., Li, E., Schneider, M., Russell, K.S., and Fu, X.Y. (2003). Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci U S A 100, 12929-34.
24. Kakinuma, Y., Miyauchi, T., Yuki, K., Murakoshi, N., Goto, K., and Yamaguchi, I. (2001). Novel molecular mechanism of increased myocardial endothelin-1 expression in the failing heart involving the transcriptional factor hypoxia-inducible factor-1alpha induced for impaired myocardial energy metabolism. Circulation 103, 2387-94.
25. Kukielka, G.L., Smith, C.W., Manning, A.M., Youker, K.A., Michael, L.H., and Entman, M.L. (1995). Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 92, 1866-75.
26. Kutsuna, F. (1972). Electron microscopic studies on isoproterenol-induced myocardial lesion in rats. Jpn Heart J 13, 168-75.
27. Larkin, J.E., Frank, B.C., Gaspard, R.M., Duka, I., Gavras, H., and Quackenbush, J. (2004). Cardiac transcriptional response to acute and chronic angiotensin II treatments. Physiol Genomics 18, 152-66.
28. Li, P., Li, J., Feng, X., Li, Z., Hou, R., Han, C., and Zhang, Y. (2003). Gene expression profile of cardiomyocytes in hypertrophic heart induced by continuous norepinephrine infusion in the rats. Cell Mol Life Sci 60, 2200-9.
29. Lowes, B.D., Gilbert, E.M., Abraham, W.T., Minobe, W.A., Larrabee, P., Ferguson, D., Wolfel, E.E., Lindenfeld, J., Tsvetkova, T., Robertson, A.D., Quaife, R.A., and Bristow, M.R. (2002). Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346, 1357-65.
30. Ma, X.L., Kumar, S., Gao, F., Louden, C.S., Lopez, B.L., Christopher, T.A., Wang, C., Lee, J.C., Feuerstein, G.Z., and Yue, T.L. (1999). Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99, 1685-91.
31. Maruffo, C.A. (1967). Fine structural study of myocardial changes induced by isoproterenol in rhesus monkeys (Macaca mulatta). Am J Pathol 50, 27-37.
32. Masino, A.M., Gallardo, T.D., Wilcox, C.A., Olson, E.N., Williams, R.S., and Garry, D.J. (2004). Transcriptional regulation of cardiac progenitor cell populations. Circ Res 95, 389-97.
33. Mercadier, J.J., Lompre, A.M., Wisnewsky, C., Samuel, J.L., Bercovici, J., Swynghedauw, B., and Schwartz, K. (1981). Myosin isoenzyme changes in several models of rat cardiac hypertrophy. Circ Res 49, 525-32.
34. Pasque, M.K., and Wechsler, A.S. (1984). Metabolic intervention to affect myocardial recovery following ischemia. Ann Surg 200, 1-12.
35. Ritchie, R.H., and Delbridge, L.M. (2006). Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect? Clin Exp Pharmacol Physiol 33, 159-66.
36. Rohrer, D.K., Chruscinski, A., Schauble, E.H., Bernstein, D., and Kobilka, B.K. (1999). Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem 274, 16701-8.
37. Rona, G., Chappell, C.I., Balazs, T., and Gaudry, R. (1959). An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Arch Pathol 67, 443-55.
38. Rothermel, B.A., McKinsey, T.A., Vega, R.B., Nicol, R.L., Mammen, P., Yang, J., Antos, C.L., Shelton, J.M., Bassel-Duby, R., Olson, E.N., and Williams, R.S. (2001). Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 98, 3328-33.
39. Sack, M.N., Rader, T.A., Park, S., Bastin, J., McCune, S.A., and Kelly, D.P. (1996). Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94, 2837-42.
40. Saito, H., Patterson, C., Hu, Z., Runge, M.S., Tipnis, U., Sinha, M., and Papaconstantinou, J. (2000). Expression and self-regulatory function of cardiac interleukin-6 during endotoxemia. Am J Physiol Heart Circ Physiol 279, H2241-8.
41. Sharma, S., Ying, J., Razeghi, P., Stepkowski, S., and Taegtmeyer, H. (2006). Atrophic remodeling of the transplanted rat heart. Cardiology 105, 128-36.
42. Sidhu, J.S., and Kaski, J.C. (2001). Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease. Heart 86, 255-8.
43. Singh, K., Communal, C., Sawyer, D.B., and Colucci, W.S. (2000). Adrenergic regulation of myocardial apoptosis. Cardiovasc Res 45, 713-9.
44. Strom, C.C., Aplin, M., Ploug, T., Christoffersen, T.E., Langfort, J., Viese, M., Galbo, H., Haunso, S., and Sheikh, S.P. (2005). Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. Febs J 272, 2684-95.
45. Takano, H., Hasegawa, H., Nagai, T., and Komuro, I. (2003). The role of PPARgamma-dependent pathway in the development of cardiac hypertrophy. Drugs Today (Barc) 39, 347-57.
46. Van Eyk, J.E., Powers, F., Law, W., Larue, C., Hodges, R.S., and Solaro, R.J. (1998). Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res 82, 261-71.
47. Wold, L.E., Aberle, N.S., 2nd, and Ren, J. (2005). Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect Prev 29, 294-9.
48. Yamauchi-Takihara, K., Ihara, Y., Ogata, A., Yoshizaki, K., Azuma, J., and Kishimoto, T. (1995). Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 91, 1520-4.
49. Yasukawa, H., Hoshijima, M., Gu, Y., Nakamura, T., Pradervand, S., Hanada, T., Hanakawa, Y., Yoshimura, A., Ross, J., Jr., and Chien, K.R. (2001). Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 108, 1459-67.
50. Yin, F., Li, P., Zheng, M., Chen, L., Xu, Q., Chen, K., Wang, Y.Y., Zhang, Y.Y., and Han, C. (2003). Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart. J Biol Chem 278, 21070-5.
51. Zhu, W., Zou, Y., Aikawa, R., Harada, K., Kudoh, S., Uozumi, H., Hayashi, D., Gu, Y., Yamazaki, T., Nagai, R., Yazaki, Y., and Komuro, I. (1999). MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 100, 2100-7.